Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Oral fluoroquinolone use and the risk of aortic and mitral valve regurgitation : a nationwide cohort study

Nibell, Olof LU ; Björk, Jonas LU orcid and Inghammar, Malin LU (2026) In BMJ Open 16(2).
Abstract

Objective This study aims to investigate whether oral fluoroquinolone use is associated with an increased risk of aortic and mitral valve regurgitation. Design A nationwide cohort study based on linked healthcare register data encompassing patient characteristics, prescription data and cases of aortic and mitral valve regurgitation. Setting Sweden, 2006–2018. Participants Study participants were adults aged 18–75 years. 794 588 courses of fluoroquinolones (88% ciprofloxacin) propensity score-matched (1:1) to an equal number of courses of penicillin V. Main outcome measures Aortic or mitral valve regurgitation leading to ED visit, hospitalisation or death. Cox regression was used to estimate HRs for the first incident of valve... (More)

Objective This study aims to investigate whether oral fluoroquinolone use is associated with an increased risk of aortic and mitral valve regurgitation. Design A nationwide cohort study based on linked healthcare register data encompassing patient characteristics, prescription data and cases of aortic and mitral valve regurgitation. Setting Sweden, 2006–2018. Participants Study participants were adults aged 18–75 years. 794 588 courses of fluoroquinolones (88% ciprofloxacin) propensity score-matched (1:1) to an equal number of courses of penicillin V. Main outcome measures Aortic or mitral valve regurgitation leading to ED visit, hospitalisation or death. Cox regression was used to estimate HRs for the first incident of valve regurgitation within 120 days of treatment initiation. Subgroup and supplementary analyses included sex, age, first episode, surgery or death only, 356-day follow-up and analysis using amoxicillin as comparator drug. Results There were 29 (incidence rate 0.5 per 1000 person-years) cases in the fluoroquinolone group compared with 43 (0.7 per 1000 person-years) cases in the penicillin V group during the main (1–30days) follow-up period; corresponding to a HR 0.70 (95% CI 0.43 to 1.11). Analyses of subsequent time periods yielded results consistent with the main period: HR 1.06 (0.63–1.78) for days 31–60 and 0.90 (0.59–1.36)days 61–120. No significant differences were found in any of the subgroup- or supplementary analyses. The absolute risk difference was −17 (95% CI −33 to 6)cases of valve regurgitation per 1 000 000 courses of fluoroquinolones. Conclusion In a nationwide cohort study, there was no statistical support for an increase in the risk of mitral or aortic valve regurgitation associated with oral fluoroquinolone use.

(Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cardiology, Epidemiology, Pharmacology
in
BMJ Open
volume
16
issue
2
article number
e096783
publisher
BMJ Publishing Group
external identifiers
  • scopus:105029835032
  • pmid:41667182
ISSN
2044-6055
DOI
10.1136/bmjopen-2024-096783
language
English
LU publication?
yes
id
d9bef197-d1ba-409e-953b-da465ca422c8
date added to LUP
2026-04-17 11:52:50
date last changed
2026-06-26 18:44:35
@article{d9bef197-d1ba-409e-953b-da465ca422c8,
  abstract     = {{<p>Objective This study aims to investigate whether oral fluoroquinolone use is associated with an increased risk of aortic and mitral valve regurgitation. Design A nationwide cohort study based on linked healthcare register data encompassing patient characteristics, prescription data and cases of aortic and mitral valve regurgitation. Setting Sweden, 2006–2018. Participants Study participants were adults aged 18–75 years. 794 588 courses of fluoroquinolones (88% ciprofloxacin) propensity score-matched (1:1) to an equal number of courses of penicillin V. Main outcome measures Aortic or mitral valve regurgitation leading to ED visit, hospitalisation or death. Cox regression was used to estimate HRs for the first incident of valve regurgitation within 120 days of treatment initiation. Subgroup and supplementary analyses included sex, age, first episode, surgery or death only, 356-day follow-up and analysis using amoxicillin as comparator drug. Results There were 29 (incidence rate 0.5 per 1000 person-years) cases in the fluoroquinolone group compared with 43 (0.7 per 1000 person-years) cases in the penicillin V group during the main (1–30days) follow-up period; corresponding to a HR 0.70 (95% CI 0.43 to 1.11). Analyses of subsequent time periods yielded results consistent with the main period: HR 1.06 (0.63–1.78) for days 31–60 and 0.90 (0.59–1.36)days 61–120. No significant differences were found in any of the subgroup- or supplementary analyses. The absolute risk difference was −17 (95% CI −33 to 6)cases of valve regurgitation per 1 000 000 courses of fluoroquinolones. Conclusion In a nationwide cohort study, there was no statistical support for an increase in the risk of mitral or aortic valve regurgitation associated with oral fluoroquinolone use.</p>}},
  author       = {{Nibell, Olof and Björk, Jonas and Inghammar, Malin}},
  issn         = {{2044-6055}},
  keywords     = {{Cardiology; Epidemiology; Pharmacology}},
  language     = {{eng}},
  number       = {{2}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{BMJ Open}},
  title        = {{Oral fluoroquinolone use and the risk of aortic and mitral valve regurgitation : a nationwide cohort study}},
  url          = {{http://dx.doi.org/10.1136/bmjopen-2024-096783}},
  doi          = {{10.1136/bmjopen-2024-096783}},
  volume       = {{16}},
  year         = {{2026}},
}